As HIF pathway modulation had a differential effect on CKD progression depending on the approach used, with a more favourable effect expected with pharmacologic modulations, we tested in vivo a specific FIH inhibitor, DM-NOFD. This evidence concerns the gene CASR and chronic kidney disease.